Lin Zhe-Zhong, Chang Wei-Ting, Chiang Chun-Yen, Chen Zhih-Cherng, Ku Po-Ming
Department of Cardiology, Chi Mei Medical Center, Liouying; ; Department of Leisure and Sports Management, Far East University.
Department of Cardiology, Chi Mei Medical Center, Yongkang.
Acta Cardiol Sin. 2017 Jan;33(1):92-95. doi: 10.6515/acs20160328a.
Bioresorbable vascular scaffold (BVS) implantation has been shown to be safe in patients with stable coronary disease, and effective against the thrombotic lesion and the in-stent restenosis (ISR) of the drug-eluting stent (DES). BVSs have the advantages of a snow racket concept, positive vessel remodeling, and better conformability compared with DES in acute coronary syndrome (ACS). We report on a young patient with ST-elevation myocardial infarction (STEMI) who presented to our emergency department arising from very late stent thrombosis (VLST) of a 2.5 × 28 mm paclitaxel-eluting stent (Coroflex Please) three years after its implantation. After the patient was treated with balloon dilation, intravascular ultrasound (IVUS) revealed a short segment of a guide wire outside the DES mesh. Two BVSs were implanted to prevent a DES recoil. Post-scaffold-implantation IVUS showed adequately expanded strut of BVSs. Six months later, optical coherence tomography (OCT) revealed that some segments of the scaffold had been absorbed and that there was no in-scaffold restenosis. The patient had not complained about angina during the out-patient clinic follow-up. This is the first report of successful BVS implantation for a STEMI patient attributable to DES VLST.
生物可吸收血管支架(BVS)植入术已被证明在稳定性冠心病患者中是安全的,并且对药物洗脱支架(DES)的血栓性病变和支架内再狭窄(ISR)有效。与DES相比,BVS在急性冠状动脉综合征(ACS)中具有球拍概念、正向血管重塑和更好的顺应性等优点。我们报告了一名年轻的ST段抬高型心肌梗死(STEMI)患者,该患者在植入2.5×28 mm紫杉醇洗脱支架(Coroflex Please)三年后因极晚期支架血栓形成(VLST)到我们急诊科就诊。患者接受球囊扩张治疗后,血管内超声(IVUS)显示DES网眼外有一小段导丝。植入两枚BVS以防止DES回缩。支架植入后IVUS显示BVS支架充分扩张。六个月后,光学相干断层扫描(OCT)显示部分支架段已被吸收,且支架内无再狭窄。患者在门诊随访期间未诉心绞痛。这是首例因DES-VLST成功植入BVS治疗STEMI患者的报告。